1. Walker GV, Smith GL, Perkins GH, Oh JL, Woodward W, Yu TK, et al. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010; 116:4000–4006.
Article
2. Merson M, Andreola S, Galimberti V, Bufalino R, Marchini S, Veronesi U. Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer. 1992; 70:504–508.
Article
3. van Ooijen B, Bontenbal M, Henzen-Logmans SC, Koper PC. Axillary nodal metastases from an occult primary consistent with breast carcinoma. Br J Surg. 1993; 80:1299–1300.
Article
4. Carlson RW, Edge SB, Theriault RL. NCCN Breast Cancer Practice Guidelines Panel. NCCN: breast cancer. Cancer Control. 2001; 8:6 Suppl 2. 54–61.
5. Wang X, Zhao Y, Cao X. Clinical benefits of mastectomy on treatment of occult breast carcinoma presenting axillary metastases. Breast J. 2010; 16:32–37.
Article
6. Khandelwal AK, Garguilo GA. Therapeutic options for occult breast cancer: a survey of the American Society of Breast Surgeons and review of the literature. Am J Surg. 2005; 190:609–613.
Article
7. Buchanan CL, Morris EA, Dorn PL, Borgen PI, Van Zee KJ. Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol. 2005; 12:1045–1053.
Article
8. Olson JA Jr, Morris EA, Van Zee KJ, Linehan DC, Borgen PI. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol. 2000; 7:411–415.
Article
9. Chan SW, Cheung PS, Chan S, Lau SS, Wong TT, Ma M, et al. Benefit of ultrasonography in the detection of clinically and mammographically occult breast cancer. World J Surg. 2008; 32:2593–2598.
Article
10. Ahn SH, Park JM, Gong G. Axillary lymph node presentation with occult breast carcinoma. J Korean Surg Soc. 1998; 54:482–487.
11. Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys. 2000; 47:143–147.
Article
12. Barton SR, Smith IE, Kirby AM, Ashley S, Walsh G, Parton M. The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. Eur J Cancer. 2011; 47:2099–2106.
Article
13. Vlastos G, Jean ME, Mirza AN, Mirza NQ, Kuerer HM, Ames FC, et al. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001; 8:425–431.
Article
14. Kemeny MM, Rivera DE, Terz JJ, Benfield JR. Occult primary adenocarcinoma with axillary metastases. Am J Surg. 1986; 152:43–47.
Article
15. Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg. 1990; 125:210–214.
Article
16. Vilcoq JR, Calle R, Ferme F, Veith F. Conservative treatment of axillary adenopathy due to probable subclinical breast cancer. Arch Surg. 1982; 117:1136–1138.
Article
17. Lee WJ, Chu JS, Chang KJ, Chen KM. Occult breast carcinoma: use of color Doppler in localization. Breast Cancer Res Treat. 1996; 37:299–302.
18. Campana F, Fourquet A, Ashby MA, Sastre X, Jullien D, Schlienger P, et al. Presentation of axillary lymphadenopathy without detectable breast primary (T0 N1b breast cancer): experience at Institut Curie. Radiother Oncol. 1989; 15:321–325.
Article
19. He M, Tang LC, Yu KD, Cao AY, Shen ZZ, Shao ZM, et al. Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer. Eur J Surg Oncol. 2012; 38:1022–1028.
Article
20. Halsted WS. I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907; 46:1–19.
Article
21. El-Bastawissi AY, White E, Mandelson MT, Taplin S. Variation in mammographic breast density by race. Ann Epidemiol. 2001; 11:257–263.
Article
22. del Carmen MG, Halpern EF, Kopans DB, Moy B, Moore RH, Goss PE, et al. Mammographic breast density and race. AJR Am J Roentgenol. 2007; 188:1147–1150.
Article
23. Lee CH, Dershaw DD, Kopans D, Evans P, Monsees B, Monticciolo D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010; 7:18–27.
Article